This course has expired. View available courses.
Dermatology
Challenging cases in plaque psoriasis – optimising outcomes
This 1-hour RACP accredited activity program is designed to provide dermatologists with a contemporary clinical approach to the management of plaque psoriasis, with the aim of optimising outcomes for their patients. The program will help dermatologists explore the efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis.
This educational activity was developed by MdBriefCase at the request, and with funding from Eli Lilly.
DURATION
1.0 hr
PROFESSION
Specialist
# OF CREDITS
1
ACCREDITATION
RACP
EXPIRY DATE
2022-12-31
This 1-hour RACP accredited activity program is designed to provide dermatologists with a contemporary clinical approach to the management of plaque psoriasis, with the aim of optimising outcomes for their patients. The program will help dermatologists explore the efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis.
This educational activity was developed by MdBriefCase at the request, and with funding from Eli Lilly.
Faculty
Prof. Peter Foley,
BMedSc, MBBS, MD, FACD
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the advantages in pursuing a treatment plan with a goal of achieving a Psoriasis Area Severity Index (PASI) 100 response
- Evaluate efficacy and safety of novel targeted therapies such as ixekizumab in plaque psoriasis
- Identify patients with plaque psoriasis who would most benefit from treatment with ixekizumab
Accreditation
This interactive online learning activity is valued at 1 Hour(s) of continuing education with RACP.